Avidity Biosciences: Funding, Investors & Team (Oct 2026)
Avidity Biosciences, Inc. is at the forefront of developing a novel class of therapies called AOCs that aim to address the limitations of current oligonucleotide treatments for various serious diseases. By utilizing its proprietary AOC platform, Avidity is able to create therapeutics that combine the tissue specifiUK monoclonal antibodies with the precision of oligonucleotide therapies, allowing for targeted treatment of previously inaccessible tissue and cell types as well as more effective targeting of the underlying genetic causes of diseases. Avidity's main product candidate, AOC 1001, is intended for the treatment of myotonic dystrophy type 1, with other programs focused on treating various muscle disorders such as muscle atrophy, Duchenne muscular dystrophy, facioscapulohumeral muscular dystrophy, and Pompe disease. In addition to muscle-related diseases, Avidity is also exploring the potential of its therapies in immune and other cell types.
Avidity Biosciences has raised $1.0B across 3 funding rounds on record, the most recent an undisclosed round of $345M announced in Aug 2024.
That round is above the $8.4M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Avidity Biosciences Company Profile and Key Stats
Latest funding round on record: Aug 2024.
Avidity Biosciences Funding Rounds
Avidity Biosciences raised $207M in an undisclosed round announced in Dec 2022.
1.5 years later, an undisclosed round of $461M was announced in Jun 2024.
2 months later, an undisclosed round of $345M was announced in Aug 2024.
Avidity Biosciences Founders and Leadership Team
No contact details are on record for this team yet.
Avidity Biosciences Funding Compared to Other Biotechnology Startups
Avidity Biosciences' latest round of $345M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Avidity Biosciences in Biotechnology and San Diego
Companies Similar to Avidity Biosciences
Prolific Machines is a biotech company located in San Francisco, California, that was established in 2020. It…
Altay Therapeutics is a biotech company focused on finding and discovering small molecule therapies for…
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…
Arkea Bio creates technology aimed at reducing greenhouse gas (GHG) emissions in the agricultural sector.
Serán is a contract development and manufacturing organization providing a comprehensive suite of…
Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from…
Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from…
Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat…
Avidity Biosciences Funding FAQs
What does Avidity Biosciences do?
Avidity Biosciences, Inc. is at the forefront of developing a novel class of therapies called AOCs that aim to address the limitations of current oligonucleotide treatments for various serious diseases. By utilizing its proprietary AOC platform, Avidity is able to create therapeutics that combine the tissue specifiUK monoclonal antibodies with the precision of oligonucleotide therapies, allowing for targeted treatment of previously inaccessible tissue and cell types as well as more effective targeting of the underlying genetic causes of diseases. Avidity's main product candidate, AOC 1001, is intended for the treatment of myotonic dystrophy type 1, with other programs focused on treating various muscle disorders such as muscle atrophy, Duchenne muscular dystrophy, facioscapulohumeral muscular dystrophy, and Pompe disease. In addition to muscle-related diseases, Avidity is also exploring the potential of its therapies in immune and other cell types.
How much funding has Avidity Biosciences raised?
Avidity Biosciences has raised $1.0B across 3 rounds on record. The most recent is an undisclosed round of $345M announced in Aug 2024.
When did Avidity Biosciences last raise funding?
Avidity Biosciences' most recent funding round on record is an undisclosed round of $345M, announced in Aug 2024.
Who founded Avidity Biosciences?
FundedIQ lists Mark E Davis (Founder), Mark E. Davis (Founder) at Avidity Biosciences.
Who is the CEO of Avidity Biosciences?
Sarah Boyce is listed as CEO at Avidity Biosciences.
Where is Avidity Biosciences headquartered?
Avidity Biosciences is based in San Diego, California, United States.
How many employees does Avidity Biosciences have?
Avidity Biosciences is in the 251-500 employee band.
How does Avidity Biosciences' funding compare to other Biotechnology startups?
Avidity Biosciences' latest round of $345M is above the $8.4M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's Avidity Biosciences Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Avidity Biosciences is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.